SEC Form 4 · accession 0001283303-26-000010
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Elizabeth E Reed
Officer — Chief Legal Officer and GC
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 9:32 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 15, 2026 | M | 37,500 | $15.46 | A | 142,889 | D | |
| Common StockF3 | Sep 15, 2026 | S | 21,926 | $62.0255 | D | 120,963 | D | |
| Common StockF4 | Sep 15, 2026 | S | 13,874 | $62.6326 | D | 107,089 | D | |
| Common StockF5 | Sep 15, 2026 | S | 1,400 | $63.6902 | D | 105,689 | D | |
| Common Stock | Sep 15, 2026 | S | 300 | $65.31 | D | 105,389 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy)F6 | $15.46 | Sep 15, 2026 | M | 37,500 | D | — | Jan 31, 2030 | Common Stock | 37,500 | 0 | D |
Explanation of responses
- F1Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
- F2This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- F3The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F4The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F5The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- F6The stock option is fully vested and exercisable.